Kriya Therapeutics: Company Profile & Valuation

Kriya Therapeutics develops AAV-based gene therapies for the treatment of Type 1 and Type 2 diabetes, severe obesity, thyroid eye disease, and other chronic conditions. Kriya Therapeutics is a fully integrated platform company pioneering novel technologies and therapeutics in gene therapy, with core operations located in Palo Alto, California, and Research Triangle Park, North Carolina, letting it draw on both Silicon Valley's innovation culture and North Carolina's manufacturing and research infrastructure.

Since its founding in 2019, Kriya has run over 100 engineering and GMP batches at 50L scale or greater, generating over 80 million proprietary data points structured in its HOPSON data platform that powers the intelligent systems behind its product engine, which takes potential medicines from concept to clinic and beyond.

Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Kriya Therapeutics.

Often trade at a premium or discount to NAV.

Platforms match existing holders with buyers. Kriya Therapeutics availability at any moment is set by the holders.

High minimums, transfer approval, company right-of-first-refusal.

Valuations, rounds and IPO status for every company in the directory — Kriya Therapeutics included.

Lead investors for each round are in the funding timeline.

The closest gene therapy and biotech peers are on the competitors page.

The routes section explains what is realistically available for a company at this stage.

No. Kriya Therapeutics is a private company; its shares do not trade on a public exchange.